FDA review uncertainty, failed phase 3 for ersodetug in HI, high-risk upLIFT trial, tight cash runway—read more macro ...
Absci Corporation downgraded to Hold as ABS-101 stalls and focus shifts to ABS-201; cash runway to H1 2028, but risks persist ...
Andrew Beattie was part of the original editorial team at Investopedia and has spent twenty years writing on a diverse range of financial topics including business, investing, personal finance, and ...
A therapeutic plasma exchange (TPE) recently saved the life of a puppy that overdosed on a non-steroidal anti-inflammatory ...
Editorial Note: We earn a commission from partner links on Forbes Advisor. Commissions do not affect our editors' opinions or evaluations. Disclaimer: Calculator results and default inputs are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results